Mutations in the THBD gene — previously suggested to predispose people to atypical hemolytic uremic syndrome (aHUS) — might not make any significant contribution to the disease’s development and its severity, according to a small Spanish study. The mutations were found in Spanish aHUS patients at similar frequencies to…
Relapses were less likely in people with atypical hemolytic uremic syndrome (aHUS) treated with Soliris (eculizumab) after a kidney transplant, and they had better kidney function and a lower risk of transplant rejection, according to a meta-analysis of published studies. “This meta-analysis … demonstrated that [Soliris] produced meaningful…
The safety profile of Soliris (eculizumab) in real-world practice is similar to that reported in clinical trials, according to a large analysis of data from Japan. “This is the largest safety dataset on [Soliris] in Japan derived from more than 10 years of clinical experience,” the researchers wrote. “No…
Genetic screening of a large group of people suspected of having atypical hemolytic uremic syndrome (aHUS) detected very few gene variants likely to be associated with the condition, a study reported. Despite signs of aHUS, around two-thirds of those tested had no evidence of any known disease-causing variants. These…
Most patients and caregivers living with atypical hemolytic uremic syndrome (aHUS) prefer Ultomiris (ravulizumab-cwvz) over Soliris (eculizumab), a new study reports. The fact that Ultomiris is administered less often than Soliris was viewed as a key factor that separates the two medications and patients on Ultomiris were…
A case study of atypical hemolytic uremic syndrome (aHUS) caused by a new mutation in the DGKE gene highlights the disease’s early onset and severe difficult-to-treat course. The report, “Clinical features and management of atypical hemolytic uremic syndrome patient with DGKE gene variants: a case report,”…
A young adult with atypical hemolytic uremic syndrome (aHUS) in India successfully received a transplanted kidney from a donor with an incompatible blood type, a recent case study says. The report — the first to document such a case in someone diagnosed with aHUS — demonstrates that blood-type-incompatible…
Soliris (eculizumab) was effective in enhancing kidney disease-free survival in patients with atypical hemolytic uremic syndrome (aHUS), a real-world study reported. Specifically, data showed Soliris was able to increase patients’ five-year survival rate without signs of kidney disease by nearly five times. According to authors, this was the…
Areas of brain damage caused by a lack of blood supply were found in a patient with atypical hemolytic uremic syndrome (aHUS), a case study reports. Treatment with Soliris (eculizumab) ultimately resolved the patient’s neurological symptoms. According to the authors, the case shows this type of brain damage…
A boy with atypical hemolytic uremic syndrome (aHUS) experienced a disease relapse followed by unusual symptoms, including bone tissue death and gallstones, after pausing treatment with Soliris (eculizumab). His case was described in the report, “Bilateral hip osteonecrosis and cholelithiasis after eculizumab discontinuation in atypical…
Get regular updates to your inbox.